scholarly journals Mechanisms of tolerance induction: blockade of co–stimulation

2001 ◽  
Vol 356 (1409) ◽  
pp. 649-657 ◽  
Author(s):  
Fabien Sebille ◽  
Bernard Vanhove ◽  
Jean-Paul Soulillou

Induction of tolerance to transplantation antigens is believed to be a promising way to achieve long–term allograft survival without a deleterious immunosuppressive regimen. T–cell activation, which is an essential feature of graft rejection, requires a first signal provided by T–cell receptor (TCR) ligation and a second signal provided by engagement of co–stimulatory molecules with their respective ligands on antigen–presenting cells. The coordinated triggering of these two independent signalling systems ensures the full T–cell activation, including proliferation and acquisition of effector function. TCR occupancy in the absence of co–stimulatory signals leads to a sustained loss of antigen responsiveness called clonal anergy, which could be of major importance in transplantation. In vivo , co–stimulation blockade was indeed shown to allow for long–term allograft survival in several transplantation models. However, the current continuous identification of new co–stimulatory molecules suggests that a functional redundancy of the system exists and that tolerance to transplantation antigens might be achieved more easily through the combined blockade of two or several co–stimulatory signals. In this review, we analyse the biological effects of the disruption of some co–stimulation pathways in vitro and in vivo and discuss their potential interest for tolerance induction.

1993 ◽  
Vol 178 (5) ◽  
pp. 1801-1806 ◽  
Author(s):  
H Lin ◽  
S F Bolling ◽  
P S Linsley ◽  
R Q Wei ◽  
D Gordon ◽  
...  

Allograft rejection is a T cell-dependent process. Productive T cell activation by antigen requires antigen engagement of the T cell receptor as well as costimulatory signals delivered through other T cell surface molecules such as CD28. Engagement of CD28 by its natural ligand B7 can be blocked using a soluble recombinant fusion protein, CTLA4Ig. Administration of CTLA4Ig blocks antigen-specific immune responses in vitro and in vivo, and we have shown that treatment of rats with a 7-d course of CTLA4Ig at the time of transplantation leads to prolonged survival of cardiac allografts (median 30 d), although most grafts are eventually rejected. Here, we have explored additional strategies employing CTLA4Ig in order to achieve long-term allograft survival. Our data indicate that donor-specific transfusion (DST) plus CTLA4Ig can provide effective antigen-specific immunosuppression. When DST is administered at the time of transplantation followed by a single dose of CTLA4Ig 2 d later, all animals had long-term graft survival (> 60 d). These animals had delayed responses to donor-type skin transplants, compared with normal rejection responses to third-party skin transplants. Furthermore, donor-matched second cardiac allografts were well tolerated with minimal histologic evidence of rejection. These data indicate that peritransplant use of DST followed by subsequent treatment with CTLA4Ig can induce prolonged, often indefinite, cardiac allograft acceptance. These results may be clinically applicable for cadaveric organ and tissue transplantation in humans.


1997 ◽  
Vol 138 (2) ◽  
pp. 271-281 ◽  
Author(s):  
Jes Dietrich ◽  
Jesper Kastrup ◽  
Bodil L. Nielsen ◽  
Niels Ødum ◽  
Carsten Geisler

Several receptors are downregulated by internalization after ligand binding. Regulation of T cell receptor (TCR) expression is an important step in T cell activation, desensitization, and tolerance induction. One way T cells regulate TCR expression is by phosphorylation/dephosphorylation of the TCR subunit clusters of differentiation (CD)3γ. Thus, phosphorylation of CD3γ serine 126 (S126) causes a downregulation of the TCR. In this study, we have analyzed the CD3γ internalization motif in three different systems in parallel: in the context of the complete multimeric TCR; in monomeric CD4/CD3γ chimeras; and in vitro by binding CD3γ peptides to clathrin-coated vesicle adaptor proteins (APs). We find that the CD3γ D127xxxLL131/132 sequence represents one united motif for binding of both AP-1 and AP-2, and that this motif functions as an active sorting motif in monomeric CD4/ CD3γ molecules independently of S126. An acidic amino acid is required at position 127 and a leucine (L) is required at position 131, whereas the requirements for position 132 are more relaxed. The spacing between aspartic acid 127 (D127) and L131 is crucial for the function of the motif in vivo and for AP binding in vitro. Furthermore, we provide evidence indicating that phosphorylation of CD3γ S126 in the context of the complete TCR induces a conformational change that exposes the DxxxLL sequence for AP binding. Exposure of the DxxxLL motif causes an increase in the TCR internalization rate and we demonstrate that this leads to an impairment of TCR signaling. On the basis of the present results, we propose the existence of at least three different types of L-based receptor sorting motifs.


2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii96-ii97
Author(s):  
Teresa Nguyen ◽  
Dong Ho Shin ◽  
Hong Jiang ◽  
Derek Wainwright ◽  
Sagar Sohoni ◽  
...  

Abstract Immune enhancement of virotherapy by reshaping the tumor immune landscape may improve its success rates. IDO, an IFNγ inducible tryptophan catabolizing enzyme, is upregulated in glioblastoma, correlating with poor prognoses. IDO-mediated tryptophan depletion in the tumor-microenvironment decreases proliferation and induces apoptosis of surrounding effector T-cells. Kynurenine, a metabolite of tryptophan, induces T-cell differentiation into immunosuppressive Tregs. Excess kynurenine elicits AhR-mediated lymphocyte dysfunction and immunosuppression. The immune stimulating effect of oncolytic-virus, Delta-24-RGDOX, triggers IFNγ production contributing to a positive IDO-Kynurenine-AhR feedback loop. We hypothesized that combining Delta-24-RGDOX with IDO inhibitors will synergize to effectively treat glioblastoma. We characterized IDO and AhR in Delta-24-RGDOX infected cancers using immunofluorescence, qRT-PCR, and flow cytometry and found increased expression of both proteins in vitro and in vivo. We also observed induction of AhR in CD4+ and CD8+ T-cells by Delta-24-RGDOX in vivo. Delta-24-RGDOX also increased activity of AhR in cancer cells as indicated by an AhR responsive elements transcription assay. We used a murine glioblastoma model to test the efficacy of combining Delta-24-RGDOX with IDO inhibitor, 1MT/indoximod; the combination produced 30% more long-term survivors compared Delta-24-RGDOX alone (P=0.03), which we showed, through lymphocytic depletion studies, was dependent on CD4+ T-cell activation. We observed 100% survival in the re-challenged long-term glioblastoma survivors, indicating the establishment of immune memory by the combination. Functional studies showed significant increases in anti-tumor activity of splenocytes from combination-treated mice compared to Delta-24-RGDOX-treated mice (P=0.009). Flow cytometry studies revealed that combination-treated mice yielded the highest levels of chronically activated T-cells and lowest levels of Tregs and myeloid derived suppressor cells compared to Delta-24-RGDOX single treatment (P≤0.05). This microenvironment remodeling correlated with complete tumor elimination. Altogether, Delta-24-RGDOX activates the IDO-Kyn-AhR cascade in gliomas, identifying new targets, which when inhibited have the potential to enhance the anti-glioma effect of oncolytic-viruses by reversing tumor immunosuppression.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2596-2596
Author(s):  
Li Liu ◽  
Bradley S. Fletcher

Abstract Gene therapy in adult hemophilia A mice is known to generate a robust immune response against the newly produced FVIII protein. This phenomenon has been extensively reported for both viral and non-viral vectors. T cell activation promotes the proliferation of B cells that produce antibodies against FVIII (inhibitors) leading to a loss of circulating FVIII protein and activity. Approaches to attenuate this immune response have included the use of cytotoxic chemotherapeutic agents (such as cyclophosphamide) or the use of antibodies or soluble fusion proteins that prevent T cell activation (such as the fusion protein between the cytotoxic T lymphocyte-associated antigen 4 and the immunoglobulin heavy chain, CTLA-4-Ig). Recently, the mechanism by which CTLA-4-Ig exerts its effect has been elucidated and is thought to involve tryptophan catabolism by upregulation of the enzyme indoleamine 2,3-dioxygenase (IDO). Catabolites of tryptophan degradation, such as kynurenine, have been shown to block T cell proliferation and promote T cell apoptosis. Here we report that hydrodynamic co-administration of Sleeping Beauty transposons encoding both FVIII and IDO are able to attenuate, but not fully block, inhibitor formation. With this approach, long term expression of FVIII at therapeutic levels (∼10% of normal) can be achieved in adult animals without the need for additional immune suppression. Only in animals receiving FVIII and IDO together can we detect FVIII protein by western blot at 24 weeks. Serum kynurenine levels are slightly elevated after gene delivery in animals receiving the IDO gene, but fall to within normal levels by 24 weeks. These results suggest that modulation of the levels of tryptophan catabolites in vivo can influence the formation of FVIII inhibitors.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2430-2430
Author(s):  
Davide Bagnara ◽  
Philip Chum ◽  
Kanti R Rai ◽  
Nicholas Chiorazzi

Abstract Abstract 2430 B-cell type chronic lymphocytic leukemia (CLL), an incurable disease of unknown etiology, results from the clonal expansion of a CD5+CD19+ B lymphocyte. Our previous study indicated a key role of autologous T cell activation in the successful engraftment and proliferation of CLL cells in NOD/SCID/gcnull (NSG) mice. This T-cell activation, however, was eventually detrimental as it led to CTL generation and elimination of the leukemic clone. By analyzing a panel of human cytokines in the sera of mice treated in different ways in the xenogeneic model, we identified sCD40L as a molecule that correlated with the level of CLL proliferation regardless of T-cell abundance. To determine if sCD40L was really responsible for CLL proliferation in vivo, we preconditioned NSG mice with human sCD40L by delivering into mouse liver an expression vector coding for hCD40L using the hydrodynamic gene delivery technique; this permitted hepatocytes to produce and secrete the soluble protein. This technique uses hydrodynamic force, generated by an injection of a large volume (10% of body weight) of DNA solution (30μg/ml) over 5–7 seconds through a blood vessel (tail vein), to permeabilize the capillary endothelium of the liver and generate “pores” in the plasma membrane of the surrounding parenchymal cells, thereby allowing DNA to reach the cell interior. With time, membrane pores close, trapping these molecules inside. At that point, transfected cells transiently produce the molecule encoded by the vector. We generated a CD40L construct consisting of the soluble part of CD40L and the trimerization domain of adiponectin (ADPN-CD40L). The adiponectin domain creates a trimer which can also dimerize to a hexamer, creating a multimeric form with higher biological activity. Furthermore, glycosylation of adiponectin increases the stability of the molecule. After hydrodynamic gene delivery of the ADPN-CD40L expression vector, high levels of ADPN-CD40L (> 5ng/ml) were found in the sera of treated mice for over two months. Next, CFSE-labeled CLL PBMCs were injected in these mice. Untreated mice and mice co-injected with allogeneic monocytes served as negative and positive controls. Ten days after CLL cell injection into mice with circulating ADPN-CD40L, we documented leukemia cell proliferation in the blood and spleen by CFSE dilution for every CLL sample studied, although the degree of proliferation varied among samples. Nevertheless, proliferation could be extensive with leukemic cells from some cases undergoing more than 6 rounds of division. In contrast, there was no proliferation in untreated mice or negligible/minimal CLL cell proliferation in mice receiving monocytes, probably because the time point was too early to permit autologous T-cell expansion and consequentially CLL cell proliferation. Currently the effects of other cytokines, alone or in combination with ADPN-CD40L, on engraftment and long term growth of CLL cells in vivo are being studied. Thus, this approach appears to reduce/eliminate a down side of our initial model whereby necessary but uncontrolled T-cell expansion to alloantigens generated GVHD and GVL making the model short term. This new approach may lead to a long term model that would allow more complex preclinical studies or would be a better tool to study the basic biology of CLL cells in vivo. Disclosures: No relevant conflicts of interest to declare.


1995 ◽  
Vol 6 (4) ◽  
pp. 1143-1150 ◽  
Author(s):  
M H Sayegh ◽  
L A Turka

It is now accepted that T cells need two signals for full activation. The first is the foreign antigen itself presented by self-major histocompatibility complex and thus provides antigen specificity to the immune response. The second is a "costimulatory" signal, the best-characterized of which is provided through the T cell accessory molecule CD28. In vitro, the blockade of costimulatory signals inhibits T cell activation and induces a state of antigen-specific unresponsiveness. In vivo, agents that block CD28-mediated costimulation have proved extremely effective in inhibiting the immune response in experimental models of transplantation and autoimmune disease, providing novel strategies for use in clinical trials in the near future.


1997 ◽  
Vol 155 (3) ◽  
pp. 491-500 ◽  
Author(s):  
JJ Corrales ◽  
A Lopez ◽  
J Ciudad ◽  
MT Mories ◽  
JM Miralles ◽  
...  

At present, the in vivo response of T, B and natural killer (NK) cells to antithyroid drug therapy remains largely unknown. In the present study, we have prospectively analyzed the in vivo effects of methimazole treatment on a large number of circulating T and NK cell subsets, some of them expressing cell surface activation antigens involved in the very early phase of the immune response, in a group of 17 hyperthyroid, untreated patients with Graves' disease (GD). As one of the first events during T cell activation is the expression of interleukin (IL) receptors, we also studied the binding of IL-2 and IL-6 to T cells. Patients with Graves' disease were sequentially studied at diagnosis/before treatment (day 0) and 7, 14, 30, 90 and 180 days after methimazole therapy. The results were compared with both a group of 19 age- and sex-matched control volunteers and a group of 20 untreated/euthyroid patients with Graves' disease in long-term remission. The combination of flow cytometry and three-color immunofluorescence revealed a clear (P < 0.01) decrease in the percentage of NK cells before and during the whole course of therapy with respect to both controls and patients with Graves' disease who were in long-term remission. Before therapy, a marked increase (P < 0.001) in the ratio of B to NK cells was also observed; thereafter, a slight decrease in this ratio was observed, although normal values were detected only in patients in long-term remission. Expression of the CD69 early activation antigen in the hyperthyroid untreated patients with Graves' disease was clearly increased (P < 0.01) with respect to both controls and patients with Graves' disease who were in long-term remission. This abnormal CD69 expression was found to be significantly reduced (P < 0.001) by methimazole therapy, and this represents a new effect of the drug. Expression of the low-affinity receptor for IL-2 (CD25)--another early T cell activation marker--was not altered in Graves' disease, but the binding of IL-2 and IL-6 to T cells exhibited a progressive and parallel increase during the first 30 days of therapy, decreasing thereafter. Our results show that methimazole therapy downregulates the abnormally high expression of the CD69 early activation antigen on T cells, being less effective on inducing changes in other T cell activation markers and in NK cells.


Sign in / Sign up

Export Citation Format

Share Document